Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003417priorityCriticalpatent/ECSP003417A/en
Publication of ECSP003417ApublicationCriticalpatent/ECSP003417A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Se proveen métodos para tratar cancer, que comprenden administrar (1) un inhibidor de transferasa de proteína farnesilo conjuntamente con (2) un inhibidor de la vía de señalización Ras adicional para inducir regresión del tumor y muerte de las células cancerosas.Methods of treating cancer are provided, which comprise administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an additional Ras signaling pathway inhibitor to induce tumor regression and cancer cell death.
ECSP0034172000-04-062000-04-06
METHODS TO INDUCE THE DEATH OF CANCER CELLS AND THE REGRESSION OF TUMORS
ECSP003417A
(en)
COMBINATION OF NECROSIS INDUCTIVE SUBSTANCES WITH SUBSTANCES THAT ARE ACTIVATED BY NECROSIS, FOR THE SELECTIVE THERAPY OF TUMORS AND INFLAMMATORY DISEASES.
USE OF ASCORBIL-GAMMA-LINOLENATE OR ASCORBIL-DIHOMO-GAMMA-LINOLENATE FOR THE TREATMENT OF ASTHMA, CANCER, CARDIOVASCULAR DISEASES AND ANTI-INFLAMMATORIES.